Pyridazine compounds for inhibiting NLRP3
US12410167B2 · kind B2 · utility
0Cited by
64References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 3, 2023 |
| Grant date | Sep 9, 2025 |
| Priority date | — |
| Expiry date | Oct 3, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.